Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Operating Margin: 2010-2025

Historic Operating Margin for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to -102.85%.

  • Lineage Cell Therapeutics' Operating Margin fell 124.00% to -102.85% in Q3 2025 from the same period last year, while for Sep 2025 it was -325.27%, marking a year-over-year decrease of 6457.00%. This contributed to the annual value of -226.11% for FY2024, which is 5039.00% up from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Operating Margin is -102.85%, which was up 85.62% from -715.37% recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Operating Margin peaked at -56.48% during Q4 2021, and registered a low of -1,803.07% during Q1 2021.
  • In the last 3 years, Lineage Cell Therapeutics' Operating Margin had a median value of -304.69% in 2023 and averaged -335.10%.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Operating Margin surged by 168,094bps in 2022 and then plummeted by 36,297bps in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Operating Margin (Quarterly) stood at -56.48% in 2021, then tumbled by 29,021bps to -346.68% in 2022, then soared by 4,199bps to -304.69% in 2023, then surged by 12,652bps to -178.17% in 2024, then crashed by 124bps to -102.85% in 2025.
  • Its last three reported values are -102.85% in Q3 2025, -715.37% for Q2 2025, and -433.09% during Q1 2025.